South Korea · Delayed Price · Currency is KRW Chabiotech Statistics
Total Valuation
Chabiotech has a market cap or net worth of KRW 746.50 billion. The enterprise value is 1.81 trillion.
| Market Cap | 746.50B |
| Enterprise Value | 1.81T |
Important Dates
The next estimated earnings date is Friday, November 13, 2026.
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Chabiotech has 92.50 million shares outstanding. The number of shares has increased by 218.39% in one year.
| Current Share Class | 92.50M |
| Shares Outstanding | 92.50M |
| Shares Change (YoY) | +218.39% |
| Shares Change (QoQ) | +189.12% |
| Owned by Insiders (%) | 11.25% |
| Owned by Institutions (%) | 17.66% |
| Float | 72.88M |
Valuation Ratios
The trailing PE ratio is 59.41.
| PE Ratio | 59.41 |
| Forward PE | n/a |
| PS Ratio | 0.57 |
| PB Ratio | 0.73 |
| P/TBV Ratio | 3.13 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 126.79 |
| EV / Sales | 1.38 |
| EV / EBITDA | 27.13 |
| EV / EBIT | 191.62 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.88, with a Debt / Equity ratio of 0.79.
| Current Ratio | 0.88 |
| Quick Ratio | 0.80 |
| Debt / Equity | 0.79 |
| Debt / EBITDA | n/a |
| Debt / FCF | -2.88 |
| Interest Coverage | -1.54 |
Financial Efficiency
Return on equity (ROE) is -1.80% and return on invested capital (ROIC) is 24.34%.
| Return on Equity (ROE) | -1.80% |
| Return on Assets (ROA) | -2.01% |
| Return on Invested Capital (ROIC) | 24.34% |
| Return on Capital Employed (ROCE) | -4.66% |
| Weighted Average Cost of Capital (WACC) | -11.65% |
| Revenue Per Employee | 4.72B |
| Profits Per Employee | 51.34M |
| Employee Count | 278 |
| Asset Turnover | 0.51 |
| Inventory Turnover | 19.51 |
Taxes
In the past 12 months, Chabiotech has paid 20.13 billion in taxes.
| Income Tax | 20.13B |
| Effective Tax Rate | 544.25% |
Stock Price Statistics
The stock price has decreased by -18.40% in the last 52 weeks. The beta is 0.60, so Chabiotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.60 |
| 52-Week Price Change | -18.40% |
| 50-Day Moving Average | 9,410.00 |
| 200-Day Moving Average | 14,560.60 |
| Relative Strength Index (RSI) | 43.81 |
| Average Volume (20 Days) | 373,351 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Chabiotech had revenue of KRW 1.31 trillion and earned 14.27 billion in profits. Earnings per share was 135.82.
| Revenue | 1.31T |
| Gross Profit | 362.13B |
| Operating Income | -82.55B |
| Pretax Income | 3.70B |
| Net Income | 14.27B |
| EBITDA | -25.29B |
| EBIT | -82.55B |
| Earnings Per Share (EPS) | 135.82 |
Balance Sheet
The company has 364.24 billion in cash and 815.35 billion in debt, with a net cash position of -451.11 billion or -4,876.74 per share.
| Cash & Cash Equivalents | 364.24B |
| Total Debt | 815.35B |
| Net Cash | -451.11B |
| Net Cash Per Share | -4,876.74 |
| Equity (Book Value) | 1.03T |
| Book Value Per Share | 4,489.22 |
| Working Capital | -131.12B |
Cash Flow
In the last 12 months, operating cash flow was -100.52 billion and capital expenditures -182.60 billion, giving a free cash flow of -283.12 billion.
| Operating Cash Flow | -100.52B |
| Capital Expenditures | -182.60B |
| Depreciation & Amortization | 57.27B |
| Net Borrowing | -81.29B |
| Free Cash Flow | -283.12B |
| FCF Per Share | -3,060.67 |
Margins
Gross margin is 27.62%, with operating and profit margins of -6.30% and 1.09%.
| Gross Margin | 27.62% |
| Operating Margin | -6.30% |
| Pretax Margin | 0.28% |
| Profit Margin | 1.09% |
| EBITDA Margin | -1.93% |
| EBIT Margin | -6.30% |
| FCF Margin | n/a |
Dividends & Yields
Chabiotech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -218.39% |
| Shareholder Yield | -218.39% |
| Earnings Yield | 1.91% |
| FCF Yield | -37.93% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on June 2, 2014. It was a reverse split with a ratio of 0.7262.
| Last Split Date | Jun 2, 2014 |
| Split Type | Reverse |
| Split Ratio | 0.7262 |
Scores
Chabiotech has an Altman Z-Score of 0.8 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.8 |
| Piotroski F-Score | 3 |